Copy to clipboard 
Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as disruption-related backlogs are worked down. Unlike some of its competitors, the company reported a robust supply chain able to support accelerating growth.
Medacta’s joint replacement sales were especially strong in the first half of 2023, even when accounting for a somewhat inflated market. The company’s hip sales benefited from the Anterior Minimally Invasive Surgery Approach (AMIS), while its personalized knee solutions drove growth across all regions. Medacta’s MyShoulder and NextAR systems drove growth in its extremities category.
For 2023, the company expects sales growth in the range of 15% to 18%, implying total revenues between $542.9 million and $557 million.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $247.5 | $203.6 | $43.9 | 21.6% |
| Knees | $106.4 | $83.4 | $22.9 | 27.5% |
| Hips | $123.2 | $107.3 | $15.9 | 14.8% |
| Extremities | $17.9 | $12.9 | $5.0 | 39.1% |
| Spine | $23.6 | $20.8 | $2.8 | 13.4% |
| Sports Medicine | $0.9 | $0.6 | $0.2 | 39.1% |
| Enabling Technology | $3.7 | $3.1 | $0.6 | 17.8% |
| Total | $275.6 | $228.2 | $47.5 | 20.8% |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $82.6 | $69.3 | $13.3 | 19.2% |
| OUS | $193.0 | $158.8 | $34.2 | 21.5% |
| EMEA | $132.9 | $101.9 | $31.1 | 30.5% |
| APAC | $55.5 | $48.4 | $7.1 | 14.7% |
| ROW | $4.5 | $8.5 | ($4.0) | (46.9%) |
| Total | $275.6 | $228.2 | $47.5 | 20.8% |
Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as...
Medacta reported 1H23 orthopedic sales of €255.2 million ($275.6 million USD), +20.8% compared to the first half of 2022.
The company kept its organic growth momentum after growing more than 20% in both 2021 and 2022. In addition to continued strong performances in the EMEA region, Medacta saw recoveries in the APAC and U.S. markets as disruption-related backlogs are worked down. Unlike some of its competitors, the company reported a robust supply chain able to support accelerating growth.
Medacta’s joint replacement sales were especially strong in the first half of 2023, even when accounting for a somewhat inflated market. The company’s hip sales benefited from the Anterior Minimally Invasive Surgery Approach (AMIS), while its personalized knee solutions drove growth across all regions. Medacta’s MyShoulder and NextAR systems drove growth in its extremities category.
For 2023, the company expects sales growth in the range of 15% to 18%, implying total revenues between $542.9 million and $557 million.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $247.5 | $203.6 | $43.9 | 21.6% |
| Knees | $106.4 | $83.4 | $22.9 | 27.5% |
| Hips | $123.2 | $107.3 | $15.9 | 14.8% |
| Extremities | $17.9 | $12.9 | $5.0 | 39.1% |
| Spine | $23.6 | $20.8 | $2.8 | 13.4% |
| Sports Medicine | $0.9 | $0.6 | $0.2 | 39.1% |
| Enabling Technology | $3.7 | $3.1 | $0.6 | 17.8% |
| Total | $275.6 | $228.2 | $47.5 | 20.8% |
Orthopedic Sales by Geography
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $82.6 | $69.3 | $13.3 | 19.2% |
| OUS | $193.0 | $158.8 | $34.2 | 21.5% |
| EMEA | $132.9 | $101.9 | $31.1 | 30.5% |
| APAC | $55.5 | $48.4 | $7.1 | 14.7% |
| ROW | $4.5 | $8.5 | ($4.0) | (46.9%) |
| Total | $275.6 | $228.2 | $47.5 | 20.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
